BMS and PsiOxus to evaluate Opdivo and enadenotucirev in cancer
1 July 2016 | By Victoria White, Digital Content Producer
The companies are to evaluate the safety, tolerability and efficacy of enadenotucirev and Opdivo in a range of tumour types in late-stage cancer patients...